Abemaciclib

About

Therapy type: Targeted therapy

Therapy strategy: CDK4/6 inhibition

Mappings

NCI Thesaurus: Abemaciclib (ncit:C97660)

RxNorm: abemaciclib (rxcui:1946825, omop:792649)

SNOMED: Abemaciclib (sctid:761851004, omop:42539316)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
EMA (1) FDA (1) HSE (1)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
EMA (1) FDA (1) HSE (1)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
EMA (1) FDA (1) HSE (1)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
EMA (2) FDA (2) HSE (1)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
EMA (2) FDA (2) HSE (1)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole
EMA (2) FDA (2) HSE (1)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
EMA (2) FDA (2) HSE (1)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
EMA (1) FDA (2)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
EMA (1) FDA (2)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
EMA (1) FDA (2)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
FDA (1)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib
FDA (1)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib
FDA (1)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib
EMA (1) FDA (1) HSE (1)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
EMA (1) FDA (1) HSE (1)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane
EMA (1) FDA (1) HSE (1)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane